ProPhase Labs (NASDAQ:PRPH – Get Free Report) is expected to be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $3.77 million for the quarter.
ProPhase Labs Price Performance
NASDAQ:PRPH opened at $0.43 on Tuesday. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. The firm has a market cap of $10.25 million, a PE ratio of -0.34 and a beta of -0.53. ProPhase Labs has a 12 month low of $0.22 and a 12 month high of $7.48. The company’s 50-day moving average price is $0.42 and its two-hundred day moving average price is $1.13.
Analyst Ratings Changes
Separately, StockNews.com started coverage on ProPhase Labs in a research report on Tuesday, February 25th. They set a “sell” rating on the stock.
About ProPhase Labs
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Recommended Stories
- Five stocks we like better than ProPhase Labs
- How to Use the MarketBeat Stock Screener
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- How is Compound Interest Calculated?
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Trading Stocks: RSI and Why it’s Useful
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
